ICP-B05

N/A

Report date: 2025/06/12 11:46:58
First In Class

Base Information

Drug NameICP-B05
Drug Alias NameICPB05CM-369
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionC-C chemokine receptor type 8 inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKeymed Biosciences Co LtdInnoCare Pharma Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Tiannuo Jiancheng Pharmaceutical Technology Co LtdInnoCare Pharma LtdKeymed Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A